RU2018136203A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018136203A3 RU2018136203A3 RU2018136203A RU2018136203A RU2018136203A3 RU 2018136203 A3 RU2018136203 A3 RU 2018136203A3 RU 2018136203 A RU2018136203 A RU 2018136203A RU 2018136203 A RU2018136203 A RU 2018136203A RU 2018136203 A3 RU2018136203 A3 RU 2018136203A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662309234P | 2016-03-16 | 2016-03-16 | |
| US62/309,234 | 2016-03-16 | ||
| PCT/US2017/022663 WO2017161092A1 (en) | 2016-03-16 | 2017-03-16 | Production of antigen-specific t-cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2021107053A Division RU2021107053A (ru) | 2016-03-16 | 2017-03-16 | Получение антигенспецифических t-клеток |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018136203A RU2018136203A (ru) | 2020-04-16 |
| RU2018136203A3 true RU2018136203A3 (ru) | 2020-06-22 |
| RU2745319C2 RU2745319C2 (ru) | 2021-03-23 |
Family
ID=59850933
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018136203A RU2745319C2 (ru) | 2016-03-16 | 2017-03-16 | Получение антигенспецифических t-клеток |
| RU2021107053A RU2021107053A (ru) | 2016-03-16 | 2017-03-16 | Получение антигенспецифических t-клеток |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2021107053A RU2021107053A (ru) | 2016-03-16 | 2017-03-16 | Получение антигенспецифических t-клеток |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200291381A1 (ru) |
| EP (1) | EP3445399A4 (ru) |
| JP (1) | JP7016098B2 (ru) |
| KR (1) | KR102470979B1 (ru) |
| CN (1) | CN109475620A (ru) |
| AU (1) | AU2017233035B2 (ru) |
| CA (1) | CA3017615A1 (ru) |
| IL (1) | IL261710A (ru) |
| RU (2) | RU2745319C2 (ru) |
| SG (2) | SG11201807940XA (ru) |
| WO (1) | WO2017161092A1 (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA45491A (fr) * | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
| BR112020005552A2 (pt) * | 2017-09-20 | 2020-10-27 | Neximmune, Inc. | composições de células compreendendo células t específicas de antígeno para terapia adotiva |
| CA3077085A1 (en) | 2017-10-06 | 2019-04-11 | Oncotherapy Science, Inc. | Screening of t lymphocytes for cancer-specific antigens |
| JP2021527419A (ja) * | 2018-06-20 | 2021-10-14 | ダンマークス テクニスク ユニバーシテットＤａｎｍａｒｋｓ Ｔｅｋｎｉｓｋｅ Ｕｎｉｖｅｒｓｉｔｅｔ | 免疫細胞操作用の安定化されたｍｈｃ分子を有するスカフォールド |
| CA3110706A1 (en) * | 2018-09-19 | 2020-03-26 | FUJIFILM Cellular Dynamics, Inc. | Protein l for activation and expansion of chimeric antigen receptor-modified immune cells |
| CN109136276A (zh) * | 2018-09-30 | 2019-01-04 | 北京鼎成肽源生物技术有限公司 | 一种rfft2细胞的构建方法 |
| US20200188435A1 (en) * | 2018-11-08 | 2020-06-18 | Nexlmmune, Inc. | T cell compositions with improved phenotypic properties |
| WO2021173847A1 (en) * | 2020-02-27 | 2021-09-02 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | Cobra1/nelf-b as a booster for efficacy of cd8+ t cell-based therapy |
| WO2021262846A1 (en) * | 2020-06-26 | 2021-12-30 | The Johns Hopkins University | Adaptive nanoparticle platforms for high throughput expansion and detection of antigen-specific t cells |
| US20240066062A1 (en) * | 2020-12-11 | 2024-02-29 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| WO2023060217A1 (en) * | 2021-10-08 | 2023-04-13 | Baylor College Of Medicine | Transgenic t cell receptors targeting neoantigens for diagnosis, prevention, and/or treatment of hematological cancers |
| WO2023144275A1 (en) * | 2022-01-28 | 2023-08-03 | Katholieke Universiteit Leuven | Actuation of organoids by magnetic nanoparticles |
| DE102022132082B4 (de) | 2022-12-02 | 2024-08-08 | Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) | Verfahren zur Herstellung von genetisch transfizierten und mit Nanopartikeln und/oder einem zytotoxischen Stoff beladenen immunokompetenten Zellen sowie immunokompetente Zellen und medizinische Zusammensetzung. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2311920C2 (ru) * | 2000-09-20 | 2007-12-10 | Корикса Корпорейшн | Композиции и способы для лечения и диагностики рака легких |
| AU2003300359A1 (en) * | 2003-05-08 | 2004-12-13 | Xcyte Therapies, Inc. | Generation and isolation of antigen-specific t cells |
| AT503861B1 (de) * | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| US20120128656A1 (en) * | 2008-05-02 | 2012-05-24 | Immunovative Therapies, Ltd. | Vaccine compositions and methods |
| CN102168066A (zh) * | 2011-01-31 | 2011-08-31 | 浙江大学 | 体外诱导乙型肝炎病毒特异性细胞毒性t淋巴细胞的方法 |
| KR20210149195A (ko) * | 2012-07-13 | 2021-12-08 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 형질도입된 ｔ 세포의 투여 적합성을 평가하는 방법 |
| KR102164405B1 (ko) * | 2013-03-14 | 2020-10-12 | 더 존스 홉킨스 유니버시티 | 나노스케일 인공 항원 제시 세포 |
| US11807675B2 (en) * | 2013-10-03 | 2023-11-07 | The University Of Maryland, Baltimore | Nanoparticle based artificial antigen presenting cell mediated activation of NKT cells |
| US10066265B2 (en) * | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
| KR20160016725A (ko) * | 2014-08-05 | 2016-02-15 | 주식회사 유영제약 | 암 세포에 과발현되는 IL13Rα2에 특이적으로 결합하는 키메라 항원 수용체로 변형된 T 세포 |
-
2017
- 2017-03-16 AU AU2017233035A patent/AU2017233035B2/en active Active
- 2017-03-16 JP JP2018568171A patent/JP7016098B2/ja active Active
- 2017-03-16 RU RU2018136203A patent/RU2745319C2/ru active
- 2017-03-16 CN CN201780030022.4A patent/CN109475620A/zh active Pending
- 2017-03-16 RU RU2021107053A patent/RU2021107053A/ru unknown
- 2017-03-16 SG SG11201807940XA patent/SG11201807940XA/en unknown
- 2017-03-16 KR KR1020187029819A patent/KR102470979B1/ko active IP Right Grant
- 2017-03-16 EP EP17767506.3A patent/EP3445399A4/en active Pending
- 2017-03-16 WO PCT/US2017/022663 patent/WO2017161092A1/en active Application Filing
- 2017-03-16 CA CA3017615A patent/CA3017615A1/en active Pending
- 2017-03-16 SG SG10202008210XA patent/SG10202008210XA/en unknown
- 2017-03-17 US US16/084,121 patent/US20200291381A1/en not_active Abandoned
-
2018
- 2018-09-12 IL IL261710A patent/IL261710A/en unknown
-
2023
- 2023-02-21 US US18/111,975 patent/US20230332131A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017233035A1 (en) | 2018-11-01 |
| SG10202008210XA (en) | 2020-10-29 |
| SG11201807940XA (en) | 2018-10-30 |
| EP3445399A1 (en) | 2019-02-27 |
| AU2017233035B2 (en) | 2021-08-05 |
| IL261710A (en) | 2018-10-31 |
| KR20190026645A (ko) | 2019-03-13 |
| JP2019513412A (ja) | 2019-05-30 |
| CA3017615A1 (en) | 2017-09-21 |
| RU2018136203A (ru) | 2020-04-16 |
| US20230332131A1 (en) | 2023-10-19 |
| WO2017161092A1 (en) | 2017-09-21 |
| CN109475620A (zh) | 2019-03-15 |
| RU2745319C2 (ru) | 2021-03-23 |
| US20200291381A1 (en) | 2020-09-17 |
| RU2021107053A (ru) | 2021-08-24 |
| KR102470979B1 (ko) | 2022-11-24 |
| JP7016098B2 (ja) | 2022-02-21 |
| EP3445399A4 (en) | 2019-10-30 |